Interview
The AI Product Going Viral With Doctors: OpenEvidence, with CEO Daniel Nadler
- Open Evidence projects saving one million lives by November 4, 2034, a figure derived from an annual mortality baseline of 300,000 to 800,000 deaths due to medical errors over an eight to nine-year ramp-up period.
- Current adoption in the United States involves approximately 100,000 physicians using the platform monthly, representing 10% to 25% of active doctors, with the network expanding beyond U.S. borders.
- The platform operates via a direct-to-consumer strategy rather than waiting for enterprise or government procurement cycles, which typically require one to several years and have previously delayed market access.
- Projected doubling of medical knowledge every five years reduces the professional half-life of medical school learning to approximately two years, rendering static education insufficient for long-term practice.
- Market analysis suggests that by 2025, fewer than one percent of AI applications will effectively leverage hallucination as a functional feature, leaving 99 percent of the market available for new entrants.
- Foundational model operations are expected to become commoditized with costs converging to zero by 2030, shifting economic value and innovation focus to the application layer.
- Within ten years, personalized medicine capable of matching specific case patterns to the entirety of known medical knowledge is expected to become feasible, potentially extending life expectancy ceilings to 120 or 130 years.
- The outlook identifies uncertainty regarding AI achieving true consciousness, positing that consciousness may not be an emergent property of neural network density.